QQQ   315.68 (+0.95%)
AAPL   162.16 (+0.86%)
MSFT   283.97 (+1.23%)
META   207.84 (+1.21%)
GOOGL   100.90 (-0.48%)
AMZN   101.94 (+1.69%)
TSLA   195.87 (+1.03%)
NVDA   273.99 (+1.54%)
NIO   10.44 (+6.21%)
BABA   103.33 (+3.41%)
AMD   98.04 (+2.03%)
T   19.12 (+0.63%)
F   12.29 (+1.99%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.22%)
GE   94.07 (+0.01%)
DIS   98.07 (+1.24%)
AMC   4.90 (-2.00%)
PFE   40.36 (+0.27%)
PYPL   74.31 (+0.18%)
NFLX   339.83 (+2.35%)
QQQ   315.68 (+0.95%)
AAPL   162.16 (+0.86%)
MSFT   283.97 (+1.23%)
META   207.84 (+1.21%)
GOOGL   100.90 (-0.48%)
AMZN   101.94 (+1.69%)
TSLA   195.87 (+1.03%)
NVDA   273.99 (+1.54%)
NIO   10.44 (+6.21%)
BABA   103.33 (+3.41%)
AMD   98.04 (+2.03%)
T   19.12 (+0.63%)
F   12.29 (+1.99%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.22%)
GE   94.07 (+0.01%)
DIS   98.07 (+1.24%)
AMC   4.90 (-2.00%)
PFE   40.36 (+0.27%)
PYPL   74.31 (+0.18%)
NFLX   339.83 (+2.35%)
QQQ   315.68 (+0.95%)
AAPL   162.16 (+0.86%)
MSFT   283.97 (+1.23%)
META   207.84 (+1.21%)
GOOGL   100.90 (-0.48%)
AMZN   101.94 (+1.69%)
TSLA   195.87 (+1.03%)
NVDA   273.99 (+1.54%)
NIO   10.44 (+6.21%)
BABA   103.33 (+3.41%)
AMD   98.04 (+2.03%)
T   19.12 (+0.63%)
F   12.29 (+1.99%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.22%)
GE   94.07 (+0.01%)
DIS   98.07 (+1.24%)
AMC   4.90 (-2.00%)
PFE   40.36 (+0.27%)
PYPL   74.31 (+0.18%)
NFLX   339.83 (+2.35%)
QQQ   315.68 (+0.95%)
AAPL   162.16 (+0.86%)
MSFT   283.97 (+1.23%)
META   207.84 (+1.21%)
GOOGL   100.90 (-0.48%)
AMZN   101.94 (+1.69%)
TSLA   195.87 (+1.03%)
NVDA   273.99 (+1.54%)
NIO   10.44 (+6.21%)
BABA   103.33 (+3.41%)
AMD   98.04 (+2.03%)
T   19.12 (+0.63%)
F   12.29 (+1.99%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.22%)
GE   94.07 (+0.01%)
DIS   98.07 (+1.24%)
AMC   4.90 (-2.00%)
PFE   40.36 (+0.27%)
PYPL   74.31 (+0.18%)
NFLX   339.83 (+2.35%)

Mirati Therapeutics - MRTX Stock Forecast, Price & News

$36.78
-0.93 (-2.47%)
(As of 03/30/2023 03:58 PM ET)
Add
Compare
Today's Range
$36.17
$37.89
50-Day Range
$36.54
$54.26
52-Week Range
$32.96
$101.30
Volume
555,312 shs
Average Volume
1.16 million shs
Market Capitalization
$2.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.87

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
118.5% Upside
$80.87 Price Target
Short Interest
Bearish
14.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
1.75mentions of Mirati Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$699,126 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($13.26) to ($11.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

358th out of 999 stocks

Pharmaceutical Preparations Industry

156th out of 489 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Mirati Drops on Acceptance of Cancer Drug
Why Mirati Therapeutics Shares Are Nosediving
Why Shares of Mirati Therapeutics Fell Wednesday
SVB Securities Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)
Why Shares of Mirati Therapeutics Fell Tuesday
Mirati Therapeutics: Poised For Takeoff
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
2/28/2023
Today
3/30/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$80.87
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+120.6%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-5,957.44%
Pretax Margin
-5,953.35%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Book Value
$17.31 per share

Miscellaneous

Free Float
56,024,000
Market Cap
$2.13 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • David D. Meek
    Chief Executive Officer & Director
  • Charles M. BaumCharles M. Baum
    President, Director & Head-Research & Development
  • Laurie D. Stelzer
    Chief Financial Officer
  • James G. ChristensenJames G. Christensen
    Chief Scientific Officer & Executive VP
  • Alan Bart Sandler
    Chief Medical Officer & Executive Vice President













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

13 Wall Street analysts have issued 1-year target prices for Mirati Therapeutics' stock. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they anticipate the company's stock price to reach $80.87 in the next twelve months. This suggests a possible upside of 120.6% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX stock has decreased by 19.1% and is now trading at $36.65.
View the best growth stocks for 2023 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its earnings results on Tuesday, February, 28th. The biotechnology company reported ($3.51) EPS for the quarter, topping analysts' consensus estimates of ($3.74) by $0.23. The biotechnology company earned $0.93 million during the quarter, compared to analysts' expectations of $2.65 million. Mirati Therapeutics had a negative net margin of 5,957.44% and a negative trailing twelve-month return on equity of 66.05%. The business's revenue was up 212.4% on a year-over-year basis. During the same period in the previous year, the business posted ($3.72) EPS.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.65%), Armistice Capital LLC (6.06%), Morgan Stanley (2.93%), Price T Rowe Associates Inc. MD (2.46%), Point72 Asset Management L.P. (1.31%) and Franklin Resources Inc. (1.28%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $36.65.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.13 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($13.18) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 3/30/2023 by MarketBeat.com Staff